0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Long survival in advanced breast cancer

Mark L. Fuerst
JAMA. 1983;249(12):1538-1539. doi:10.1001/jama.1983.03330360008004.
Text Size: A A A
Published online

ABSTRACT

Adjuvant polychemotherapy can turn the mortality tables more in favor of advanced breast cancer patients, according to reports presented at a recent symposium on innovative cancer chemotherapy held in New York City.

Intensive, aggressive, postsurgical polychemotherapy, including prednisone for hormonal catabolic support, can provide a "guarantee" of an extra 2 1/2 years of life for an estimated 200,000 American women who are presently undergoing therapy for recurrent or advanced breast cancer, said Ezra M. Greenspan, MD, associate chief, Division of Medical Oncology, Mount Sinai School of Medicine, New York. Most multi-institution studies of high-risk patients with metastatic breast cancer indicate that five-year survival rarely exceeds 10% to 15%, he told the symposium.

Greenspan said, "For the high-risk patient with life-threatening [disease], there is now no question of the need for aggressive polychemotherapy."

Greenspan's statements were reinforced by data presented by Richard G. Cooper, MD, chief of oncology at Buffalo (NY)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();